Lilly(US:LLY) Ge Long Hui·2026-02-09 09:18Group 1 - Core viewpoint: Goldman Sachs has reiterated a "Buy" rating for Eli Lilly (LLY.US) and raised the target price from $114.5 billion to $126 billion, indicating strong confidence in the company's growth prospects despite increasing pricing pressures in the obesity drug market [1] - Eli Lilly's 2026 earnings guidance suggests approximately 25% year-over-year revenue growth, reflecting sustained market confidence in the obesity drug sector [1] - The company plans to launch orforglipron in the U.S. in the second quarter, with most international markets expected to follow in 2027, according to Ken Custer, head of cardiovascular metabolic health at Eli Lilly [1] Group 2 - Eli Lilly's stock price closed at $1058.18, up 3.66%, with a pre-market price of $1082.32, reflecting a 2.28% increase [2] - The stock's trading volume was 4.8871 million, with a market capitalization of $1 trillion [2] - The price-to-earnings ratio is 46.11, and the stock has a 52-week high of $1133.95, which is 31.03% lower than the current price [2]